Matchpoint Therapeutics, Inc. Asset Profile

= Subscriber Access Only

You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.

Year established

2021

Location

Cambridge MA US

Primary Industry

Biotechnology

About

Founded in 2021 and based in Massachusetts, US, Matchpoint Therapeutics, Inc. is a biotech company that focuses on the development of covalent medicines. Andre Turenne, the company's president and CEO, served as President and Chief Executive Officer of Voyager Therapeutics and Senior Vice President and Global Head of Business Development & Licensing at Sanofi. In 2022, it raised USD 30 million in seed funding co-led by new investors Atlas Venture and Access Industries. The company's key products include covalent drugs and the advanced covalent exploration (ACE) platform. The advanced covalent exploration (ACE) platform. The advanced covalent exploration (ACE) platform provides services such as pathogenic protein identification and proprietary libraries of covalent compounds.

Current Investors

Atlas Venture, Access Industries, Alexandria Venture Investments

Request a demo to show more

Primary Industry

Biotechnology

Sub Industries

Biopharmaceuticals, Oncology/Cancer Treatment, Pharmaceutical Research & Development

Website

www.matchpointtx.com

Verticals

Artificial Intelligence, HealthTech

Company Stage

Series A

Total Amount Raised

Subscriber access only

Time to go Pro

Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.